Management of Apixaban in Cases of Epistaxis
Classification of Epistaxis Severity
- In non-severe epistaxis cases, the American Academy of Otolaryngology-Head and Neck Surgery recommends not deferring the next dose of apixaban, but instead implementing local bleeding control measures before considering anticoagulant suspension 1, 2
- For patients with non-severe epistaxis, the American Academy of Otolaryngology-Head and Neck Surgery suggests continuing anticoagulant medication to avoid increasing the risk of thrombosis 1
Management Algorithm
- For non-severe epistaxis, first-line treatments include compression, vasoconstrictors, humidifying or lubricating agents, nasal cauterization, and nasal packing if necessary, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 3
- In cases of severe epistaxis, the American College of Cardiology recommends considering the administration of reversal agents, such as andexanet alfa for apixaban, if available 5, 6
- If andexanet alfa is not available, the American College of Cardiology suggests using prothrombin complex concentrate (PCC) or activated PCC 5, 6
Important Considerations
- Local control efforts are crucial because reversal strategies have associated risks, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 1
- The half-life of apixaban is 6-15 hours in patients with normal or mildly impaired renal function, which should be considered if temporary suspension is decided, according to the American College of Cardiology 5, 7
Resumption of Apixaban After Suspension
- After suspending apixaban due to severe bleeding, resumption depends on the risk of bleeding, with low-risk procedures allowing resumption the next day (24 hours later), as suggested by the American Society of Hematology 8
- For high-risk procedures, resumption is recommended 2-3 days later (48-72 hours later), according to the American Society of Hematology 8
- It is essential to evaluate the balance between thrombotic risk and re-bleeding risk before resuming anticoagulant therapy, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 2, 4